Leslie Holsinger

Currently holds a position at Quince Therapeutics Inc

Position	Company	Period
Executive Vice President - Preclinical Development	Quince Therapeutics Inc	Jan. 1, 2018 -
Vice President - Preclinical Dev.	Quince Therapeutics Inc	April 1, 2016 - Dec. 1, 2017

• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings

Download results Settings

Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other

Notification date	Transaction date	Company	B/S Transaction type	Nb. shares Price Value	Number of shares	Price	Value
2020-12-15	2020-12-14	Quince Therapeutics Inc (QNCX)	PlS Planned sale	89,531 +25.0% 34.69 US$3,642,387	89,531 +25.0%	34.69	US$3,642,387
2020-12-15	2020-12-14	Quince Therapeutics Inc (QNCX)	PlS Planned sale	32,001 -26.5% 392.67 US$1,819,481	32,001 -26.5%	392.67	US$1,819,481
2020-12-15	2020-12-14	Quince Therapeutics Inc (QNCX)	PlS Planned sale	99,994 -29.8% 362.50 US$4,922,572	99,994 -29.8%	362.50	US$4,922,572
2020-12-15	2020-12-14	Quince Therapeutics Inc (QNCX)	PlS Planned sale	13,200 -48.0% 30.91 US$408,012	13,200 -48.0%	30.91	US$408,012
2020-12-15	2020-12-14	Quince Therapeutics Inc (QNCX)	PlS Planned sale	14,275 -34.2% 30.15 US$430,391	14,275 -34.2%	30.15	US$430,391
2020-12-15	2020-12-14	Quince Therapeutics Inc (QNCX)	PlS Planned sale	1,700 -3.9% 28.80 US$48,960	1,700 -3.9%	28.80	US$48,960